Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
NICE, the healthcare guidance body, has today (Wednesday 22 February) confirmed its initial draft and final draft positive recommendation of prolonged release exenatide (Bydureon, Eli Lilly) in triple therapy regimens (in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedionei) as a treatment option for people with type 2 diabetes, when control of blood glucose remains or becomes inadequate (HbA1cii of 7.5% or above, or other higher level agreed with the individual), and the person has:
a body mass index (BMI) of 35 kg/m2 or higher in those of European family origin (with appropriate adjustment for other ethnic groups) and specific psychological or medical problems associated with high body weight, or
a BMI below 35 kg/m2, and therapy with insulin would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.
http://www.nice.org.uk/newsroom/pressreleases/ExenatideForType2Diabetes.jsp
a body mass index (BMI) of 35 kg/m2 or higher in those of European family origin (with appropriate adjustment for other ethnic groups) and specific psychological or medical problems associated with high body weight, or
a BMI below 35 kg/m2, and therapy with insulin would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.
http://www.nice.org.uk/newsroom/pressreleases/ExenatideForType2Diabetes.jsp